Two Sigma Advisers
PTGX icon

Two Sigma Advisers’s Protagonist Therapeutics PTGX Stock Holding History

Two Sigma Advisers’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,100
Closed -$545K – 2482
2024
Q3 		$545K Sell
12,100
-104,500
-90% -$4.22M ﹤0.01% 1662
2024
Q2 		$4.04M Sell
116,600
-80,100
-41% -$2.35M 0.01% 859
2024
Q1 		$5.69M Sell
196,700
-25,300
-11% -$688K 0.01% 728
2023
Q4 		$5.09M Sell
222,000
-94,900
-30% -$1.66M 0.01% 795
2023
Q3 		$5.29M Sell
316,900
-95,200
-23% -$1.85M 0.01% 702
2023
Q2 		$11.4M Sell
412,100
-37,700
-8% -$944K 0.03% 450
2023
Q1 		$10.3M Sell
449,800
-153,700
-25% -$2.58M 0.03% 544
2022
Q4 		$6.58M Buy
603,500
+196,200
+48% +$1.66M 0.02% 664
2022
Q3 		$3.43M Sell
407,300
-111,100
-21% -$1.05M 0.01% 910
2022
Q2 		$4.1M Buy
518,400
+303,700
+141% +$3.67M 0.01% 862
2022
Q1 		$5.08M Buy
214,700
+175,900
+453% +$4.96M 0.01% 796
2021
Q4 		$1.33M Sell
38,800
-106,500
-73% -$3.37M ﹤0.01% 1406
2021
Q3 		$2.58M Sell
145,300
-110,775
-43% -$4.72M 0.01% 1114
2021
Q2 		$11.5M Sell
256,075
-90,600
-26% -$2.99M 0.03% 511
2021
Q1 		$8.98M Sell
346,675
-20,600
-6% -$521K 0.02% 622
2020
Q4 		$7.4M Buy
367,275
+12,100
+3% +$260K 0.02% 676
2020
Q3 		$6.94M Sell
355,175
-64,025
-15% -$1.2M 0.02% 650
2020
Q2 		$7.4M Buy
419,200
+194,500
+87% +$2.44M 0.02% 657
2020
Q1 		$1.59M Sell
224,700
-94,300
-30% -$707K 0.01% 1234
2019
Q4 		$2.25M Buy
319,000
+166,800
+110% +$1.66M 0.01% 1170
2019
Q3 		$1.83M Buy
152,200
+27,200
+22% +$343K ﹤0.01% 1146
2019
Q2 		$1.51M Buy
125,000
+31,200
+33% +$345K ﹤0.01% 1330
2019
Q1 		$1.18M Sell
93,800
-2,400
-2% -$21.2K ﹤0.01% 1447
2018
Q4 		$647K Sell
96,200
-46,900
-33% -$372K ﹤0.01% 1670
2018
Q3 		$1.47M Sell
143,100
-14,800
-9% -$127K ﹤0.01% 1357
2018
Q2 		$1.06M Buy
157,900
+110,800
+235% +$851K ﹤0.01% 1586
2018
Q1 		$405K Buy
47,100
+29,700
+171% +$559K ﹤0.01% 1902
2017
Q4 		$362K Buy
+17,400
New +$309K ﹤0.01% 1881

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Two Sigma Advisers's PTGX Position: Q4 2024 in Review

Two Sigma Advisers sold out of Protagonist Therapeutics (PTGX) in Q4 2024, closing a stake of 12,100 shares — an estimated $545K sold.

Two Sigma Advisers first reported a position in PTGX in Q4 2017 and held it in 28 quarters. The position peaked at $11.5M in Q2 2021. 241 funds tracked by Wall St. Rank hold PTGX as of Q4 2024.

  • Two Sigma Advisers reported no remaining Protagonist Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Two Sigma Advisers sold 12,100 Protagonist Therapeutics shares in Q4 2024, an estimated $545K.
  • Two Sigma Advisers first reported a position in Protagonist Therapeutics in Q4 2017 and held it in 28 quarters.
  • Two Sigma Advisers's Protagonist Therapeutics position peaked at $11.5M in Q2 2021.
  • 241 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2024.

Based on Two Sigma Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.